Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...

The following is a summary of “Evaluating the Real-World Use of Topical Diclofenac Sodium Gel 1% Using US Longitudinal Electronic Health Records Database: A study supporting OTC switch,” published in ...

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...

African Americans, particularly women, and residents of Southern states face disproportionately high rates of SLE-related mortality.

A risk prediction score that uses machine learning and a patient’s genetic information may identify autoimmune conditions up ...

Cabaletta has been evaluating the CAR-T, called resecabtagene autoleucel or rese-cel , across six so-called RESET studies ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...